Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Polymyalgia rheumatica epidemiology and demographics
Introduction
Overview
Overview
Polymyalgia rheumatica (PMR) affects mostly subjects who are more than 50 years of age. The prevalence of PMR is highest among subjects from Scandanavian countries and those from northern European origin.
Epidemiology and Demographics
Epidemiology and Demographics
Incidence
- There is an association between PMR and giant cell arteritis. While 40 to 60% of patients with giant cell arteritis have PMR, 16 to 21% of patients with PMR develop giant cell arteritis.[1][2][3]
- The annual incidence of PMR is 64 per 100,000 population ages> 50 years.[4]
Prevalence
- PMR affects more than 700,000 subjects in the United States.[5]
Case-fatality rate/Mortality rate
- Mortality rate among individuals with PMR is similar to the general population.[4]
Age
- The incidence of polymyalgia rheumatica increases with age.
- PMR mostly affects people who are older than 50 years of age.[6][7]
- The mean age for the occurrence of PMR is 74 years.
Race
- Polymyalgia rheumatica occurs more among subjects from Scandinavian countries and those from northern European origin.[7][8]
Gender
- Females are more affected with polymyalgia rheumatica than men. [6]
References
References
- ↑ Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG (1995). “The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern”. Ann Intern Med. 123 (3): 192–4. PMID 7598301.
- ↑ Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG (1995). “Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991”. Arthritis Rheum. 38 (3): 369–73. PMID 7880191.
- ↑ Franzén P, Sutinen S, von Knorring J (1992). “Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988”. J Rheumatol. 19 (2): 273–6. PMID 1629827.
- ↑ 4.0 4.1 Raheel, Shafay; Shbeeb, Izzat; Crowson, Cynthia S.; Matteson, Eric L. (2017). “Epidemiology of Polymyalgia Rheumatica 2000-2014 and Examination of Incidence and Survival Trends Over 45 Years: A Population-Based Study”. Arthritis Care & Research. 69 (8): 1282–1285. doi:10.1002/acr.23132. ISSN 2151-464X.
- ↑ Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA; et al. (2008). “Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II”. Arthritis Rheum. 58 (1): 26–35. doi:10.1002/art.23176. PMC 3266664. PMID 18163497.
- ↑ 6.0 6.1 Doran MF, Crowson CS, O’Fallon WM, Hunder GG, Gabriel SE (2002). “Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA”. J Rheumatol. 29 (8): 1694–7. PMID 12180732.
- ↑ 7.0 7.1 Pamuk ON, Dönmez S, Karahan B, Pamuk GE, Cakir N (2009). “Giant cell arteritis and polymyalgia rheumatica in northwestern Turkey: Clinical features and epidemiological data”. Clin Exp Rheumatol. 27 (5): 830–3. PMID 19917168.
- ↑ Cimmino MA, Zaccaria A (2000). “Epidemiology of polymyalgia rheumatica”. Clin Exp Rheumatol. 18 (4 Suppl 20): S9–11. PMID 10948749.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]